Pharmala Biotech Holdings Inc. MDXXF
OTC PK
| 05/31/2026 | 02/28/2026 | 11/30/2025 | 08/31/2025 | 05/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 19.65% | 14.94% | -52.52% | -155.94% | -188.86% |
| Total Depreciation and Amortization | 22.60% | 115.95% | 313.70% | 1,434.04% | 396.92% |
| Total Amortization of Deferred Charges | -0.64% | -25.59% | -50.53% | -75.05% | 22.45% |
| Total Other Non-Cash Items | -63.84% | -72.34% | -26.96% | -2.03% | 201.62% |
| Change in Net Operating Assets | 157.96% | 155.14% | 221.22% | 143.02% | 24.23% |
| Cash from Operations | -31.30% | -27.89% | -56.19% | -215.83% | -108.11% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 180.98% | 158.56% | -257.93% | -286.50% | -148.52% |
| Cash from Investing | 180.73% | 158.34% | -259.40% | -287.76% | -148.52% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.40% | -100.00% | 99.55% | 98.05% | 108.13% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | 100.00% | 41.21% | 41.21% | -- |
| Cash from Financing | -99.54% | -100.13% | 99.21% | 97.49% | 88.27% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 89.81% | -166.34% | -369.83% | -269.08% | -3,700.00% |